-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, IM1VaHVH5XbjKEvxMCXfAjMDp8niQwVo2Q/3nA5TqOklquNheIDYKm3hj3TFmGV9 9n8HZRHyAqul46xNoIBEJA== 0000950133-98-003192.txt : 19980831 0000950133-98-003192.hdr.sgml : 19980831 ACCESSION NUMBER: 0000950133-98-003192 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980828 SROS: NONE GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH FOCUS S.A. GROUP MEMBERS: BIOTECH TARGET S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MEDIMMUNE INC /DE CENTRAL INDEX KEY: 0000873591 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521555759 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-42057 FILM NUMBER: 98700033 BUSINESS ADDRESS: STREET 1: 35 W WATKINS MILL RD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 3014170770 MAIL ADDRESS: STREET 1: 35 W WATKINS MILL ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13G/A 1 AMENDMENT NO. 1 TO SCHEDULE 13G 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* MEDIMMUNE, INC. - ------------------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $.01 PER SHARE - ------------------------------------------------------------------------------- (Title of Class of Securities) 584699102 -------------------------- CUSIP Number) - ------------------------------------------------------------------------------- (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed " for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 CUSIP No. 584699102 - ------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BB BIOTECH AG - ------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) - ------------------------------------------------------------------------------- 3. SEC Use Only - ------------------------------------------------------------------------------- 4. Citizenship or Place of Organization SWITZERLAND - ------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each Reporting ------------------------------------------------------- Person With: 6. Shared Voting Power 3,818,000 ------------------------------------------------------- 7. Sole Dispositive Power -0- ------------------------------------------------------- 8. Shared Dispositive Power 3,818,000 - ------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,818,000 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 14.5% - ------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) HC, CO - ------------------------------------------------------------------------------- Page 2 of 6 pages 3 CUSIP No. 584699102 - ------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH FOCUS S.A. - ------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - ------------------------------------------------------------------------------- 3. SEC Use Only - ------------------------------------------------------------------------------- 4. Citizenship or Place of Organization PANAMA - ------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each Reporting ------------------------------------------------------- Person With: 6. Shared Voting Power 3,818,000 ------------------------------------------------------- 7. Sole Dispositive Power -0- ------------------------------------------------------- 8. Shared Dispositive Power 3,818,000 - ------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,818,000 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 14.5% - ------------------------------------------------------------------------------- 12. Type of Reporting Person CO - ------------------------------------------------------------------------------- Page 3 of 6 pages 4 CUSIP No. 584699102 - ------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). BIOTECH TARGET S.A. - ------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (a) (b) - ------------------------------------------------------------------------------- 3. SEC Use Only - ------------------------------------------------------------------------------- 4. Citizenship or Place of Organization PANAMA - ------------------------------------------------------------------------------- Number of 5. Sole Voting Power Shares Bene- ficially -0- Owned by Each Reporting ------------------------------------------------------- Person With: 6. Shared Voting Power -0- ------------------------------------------------------- 7. Sole Dispositive Power -0- ------------------------------------------------------- 8. Shared Dispositive Power -0- - ------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person -0- 10. Check if the Aggregate Amount in Row (11) Excludes Certain shares 11. Percent of Class Represented by amount in Row (11) 0% - ------------------------------------------------------------------------------- 12. Type of Reporting Person CO - ------------------------------------------------------------------------------- Page 4 of 6 pages 5 EXPLANATORY NOTE Biotech Target S.A. ("Biotech Target") is a wholly-owned subsidiary of BB Biotech AG ("BB Biotech"). Therefore, BB Biotech may be deemed to be the beneficial owner of the shares of common stock of MedImmune, Inc. directly owned by Biotech Target. For internal purposes, on June 18, 1998 BB Biotech AG caused Biotech Target to transfer all of its holdings of securities issued by MedImmune, Inc. (consisting of the 3,818,000 shares of common stock of MedImmune, Inc.) to another wholly-owned subsidiary of BB Biotech, Biotech Focus S.A. ("Biotech Focus"). However, prior to the aforementioned transfer, as well as after the transfer of shares from Biotech Target to Biotech Focus was completed, BB Biotech was, and continues to be, the beneficial owner of the 3,818,000 shares of common stock of MedImmune, Inc. which were previously directly owned by Biotech Target, and which are now directly owned by Biotech Focus. The transfer to Biotech Focus involves no change in BB Biotech's beneficial ownership of the 3,818,000 shares of common stock of MedImmune, Inc. reported on this Schedule 13G. ITEM 2. (a) Name of Person Filing BB Biotech AG Biotech Focus S.A. Biotech Target S.A. (b) Address of Principal Business Office or, if none, Residence BB Biotech Biotech Focus Biotech Target Vordergasse 3 Swiss Bank Tower Swiss Bank Tower 8200 Schaffhausen Panama 1 Panama 1 CH/Switzerland Republic of Panama Republic of Panama (c) Citizenship See Item No. 4 of cover pages. (d) Title of Class of Securities Common Stock, Par Value $.01 Per Share (e) CUSIP Number 584699102 ITEM 4. OWNERSHIP Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,818,000 (b) Percent of class: 14.5% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote -0- (ii) Shared power to vote or to direct the vote 3,818,000 (iii) Sole power to dispose or to direct the disposition of -0- (iv) Shared power to dispose or to direct the disposition of 3,818,000 ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY This statement is filed jointly by BB Biotech, Biotech Focus and Biotech Target. Biotech Target and Biotech Focus are wholly-owned subsidiaries of BB Biotech. Page 5 of 6 pages 6 SIGNATURES After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: August 13, 1998 By: /s/ Hans-Joerg Graf --------------------- Name: Hans-Joerg Graf ------------------ Signatory Authority Date: August 13, 1998 By: /s/ Dr. Victor Bischoff ------------------------- Name: Dr. Victor Bischoff ------------------ Vice Chairman and Director BIOTECH TARGET, S.A. Date: August 13, 1998 By: /s/ Dr. Andreas Bremer ----------------------- Name: Dr. Andreas Bremer ------------------ Signatory Authority Date: August 13, 1998 By: /s/ Dr. Anders Hove -------------------- Name: Dr. Anders Hove ------------------ Signatory Authority Page 6 of 6 pages -----END PRIVACY-ENHANCED MESSAGE-----